Wells Fargo downgraded Soleno Therapeutics (SLNO) to Equal Weight from Overweight with a price target of $53, down from $110.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno’s VYKAT XR Real-World Study Adds Fuel to the Prader-Willi Investment Story
- Largest borrow rate increases among liquid names
- Soleno Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- 3 Best Trending Stocks, According to Analysts – 4/7/2026
- Arm downgraded, Arista Networks upgraded: Wall Street’s top analyst calls